Developing a new antibody to help detect pancreatic cancer during surgery
Preclinical development of a novel antibody conjugate for intraoperative detection of pancreatic cancer
This study is testing a new way to help doctors spot pancreatic cancer during surgery by using a special tool that targets cancer cells, which could lead to better treatment results for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11031402 on NIH RePORTER |
What this research studies
This research focuses on improving the detection of pancreatic cancer during surgical procedures by developing a novel antibody conjugate that targets a specific biomarker associated with the disease. The approach involves using a murine anti-MUC16 antibody that has shown promise in preclinical evaluations for its ability to bind to pancreatic cancer cells while sparing healthy tissue. By enhancing the visibility of cancerous tissues during surgery, the goal is to improve surgical outcomes and potentially increase the number of patients eligible for curative procedures.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic cancer who are undergoing surgical treatment.
Not a fit: Patients with early-stage pancreatic cancer who are not undergoing surgery or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate detection of pancreatic cancer during surgery, improving patient outcomes and survival rates.
How similar studies have performed: Other research has shown success with similar antibody-targeting approaches in cancer detection, indicating a promising avenue for this novel method.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Mohs, Aaron M. — University of Nebraska Medical Center
- Study coordinator: Mohs, Aaron M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.